Special Issue

Detection of SARS-CoV-2 Neutralizing Antibodies and Vaccine Development: 2nd Edition

Message from the Guest Editor

Neutralizing antibodies play a key role in evaluating the effectiveness of SARS-CoV-2 vaccines. There is an urgent need for standardized in vitro potency methods to assess antiviral products in both pre-clinical and clinical phases. Detecting neutralizing antibodies against SARS-CoV-2 can help understand the protective immune response in COVID-19 patients and asymptomatic cases. Currently, there are various methods for detecting SARS-CoV-2 neutralizing antibodies, but differences in laboratory procedures can lead to incomparable results. This makes it difficult to compare the immunogenicity of different vaccines. To gain a better understanding of recent scientific knowledge and current trends in SARS-CoV-2 neutralization assay and vaccine development, this Special Issue focuses on recent scientific and technical progress in this field. This Special Issue welcomes original research articles and reviews covering recent advances in novel neutralization assay development, standardization and comparison of different SARS-CoV-2 neutralization assays, comparison of neutralizing antibody responses induced by different vaccines, and correlates of protection.

Guest Editor

Dr. Jianhui Nie

Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China

Deadline for manuscript submissions

closed (31 March 2025)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/205938

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI